Download new nurse - october 2000 - NHS Greater Glasgow and Clyde

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
LUNG CANCER
January 2008
Current Awareness Bulletin
Many of the following articles are available online via the NHS Scotland eLibrary. Please use
the links where provided and your ATHENS password. A complete list of available online
journals and registration for ATHENS can be found at http://www.elib.scot.nhs.uk/
If you would like to request print copies of any of the articles please contact your nearest
library or visit the library website for further details.
http://www.nhsggc.org.uk/libraryservices
Please note that the journal articles you are accessing may be protected by copyright
legislation so there may be a limit on the number of articles you can download or print from
any single issue of a journal. If you obtain a copy via your local library's document request
service, you may be required to complete a copyright declaration form. Consult your local
library with any queries, or for further information see the website of the Copyright Licensing
Agency at www.cla.co.uk.
If you have any questions regarding this or any other library services please contact your
librarian.
Compiled by Kirsty Coltart
Library Manager
NHS Greater Glasgow & Clyde Library Network
Beatson West of Scotland Cancer Centre
Education Suite
1053 Great Western Road
G12 0YN
0141 301 7285
[email protected]
Journals received in the Beatson WoS Cancer Centre Library have been scanned for articles under the
topics listed below. I have also included some titles held in other libraries in the Network and a few from
Medline. Please use links where provided.
General
1.British Thoracic Society Standards of Care Committee. BTS statement on malignant
mesothelioma in the UK, 2007. Thorax. 62 Suppl 2:ii1-ii19, 2007 Nov.
2.Ceresoli, G. Assessment of tumor response in malignant pleural mesothelioma. Cancer
Treatment Reviews 2007 33(6): 533-541
3.Du, W. An Educational Video to Increase Clinical Trials Enrollment among Lung Cancer
Patients. Journal of Thoracic Oncology. 3(1):23-29, January 2008.
4.Madroszyk-Flandin, A. Lung cancer in elderly patients: A retrospective analysis of practice
in a single institution. Critical Reviews in Oncology/Hematology 2007 64(1): 43-48
5.O’Keeffe, P. Women and Lung Cancer. Seminars in Oncology Nursing 2008 24(1): 3-8
6.Shiau, M. Adenocarcinoma of the lung: current concepts in radiologic diagnosis and
management. Current Opinion in Internal Medicine. 6(5):526-531, October 2007.
7.Tod, A. Diagnostic delay in lung cancer: a qualitative study. Journal of Advanced Nursing.
61(3):336-343, February 2008.
Combined Modality Therapy
8.Arnold AM. Phase II study of vandetanib or placebo in small-cell lung cancer patients after
complete or partial response to induction chemotherapy with or without radiation therapy:
National Cancer Institute of Canada Clinical Trials Group Study BR.20. Journal of Clinical
Oncology. 25(27):4278-84, 2007 Sep 20.
9.Azzoli, C. Molecularly Tailored Adjuvant Chemotherapy for Resected Non-small Cell Lung
Cancer: A Time for Excitement and Equipoise. Journal of Thoracic Oncology. 3(1):84-93,
January 2008.
10.Chou, K. Phase II randomized study of weekly docetaxel alone or plus UFUR treatment in
non-small cell lung cancer patients who failed previous chemotherapy. Lung Cancer 2008
59(1): 64-68
11.Herbst RS. Phase II study of efficacy and safety of bevacizumab in combination with
chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or
refractory non small-cell lung cancer. Journal of Clinical Oncology. 25(30):4743-50, 2007 Oct
20.
12.Hirsh, V. Phase II Multicenter Trial with Carboplatin and Gemcitabine Induction
Chemotherapy Followed by Radiotherapy Concomitantly with Low-Dose Paclitaxel and
Gemcitabine for Stage IIIA and IIIB Non-small Cell Lung Cancer. Journal of Thoracic
Oncology. 2(10):927-932, October 2007.
13.Janne PA. Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB
inhibitor, for previously treated advanced non small-cell lung cancer. Journal of Clinical
Oncology. 25(25):3936-44, 2007 Sep 1.
14.Jenkins, P. Shrinkage of Locally Advanced Non–Small-Cell Lung Cancers in Response to
Induction Chemotherapy: Implications for Radiotherapy Treatment Planning. International
Journal of Radiation Oncology*Biology*Physics 2007 69(4): 993-1000
15.Nishimura, Y. Phase I/II Trial of Sequential Chemoradiotherapy Using a Novel Hypoxic
Cell Radiosensitizer, Doranidazole (PR-350), in Patients With Locally Advanced Non–SmallCell Lung Cancer (WJTOG-0002). International Journal of Radiation
Oncology*Biology*Physics 2007 69(3): 786-792
16.Pandya KJ. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in
patients with extensive-stage small-cell lung cancer who have responding or stable disease
after induction chemotherapy: a trial of the Eastern Cooperative Oncology Group (E1500).
Journal of Thoracic Oncology: 2(11):1036-41, 2007 Nov.
17.Pottgen C. Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer
treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized
trial. Journal of Clinical Oncology. 25(31):4987-92, 2007 Nov 1.
Drug Therapy
18.Bae, S. A phase II study of biweekly irinotecan and cisplatin for patients with extensive
stage disease small cell lung cancer. Lung Cancer 2008 59(1): 76-80
19.Butts CA. Randomized phase II study of gemcitabine plus cisplatin, with or without
cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung
cancer. Journal of Clinical Oncology. 25(36):5777-84, 2007 Dec 20.
20.Comella, P. Comparison of the safety and efficacy of paclitaxel plus gemcitabine
combination in young and elderly patients with locally advanced or metastatic non-small cell
lung cancerA retrospective analysis of the Southern Italy Cooperative Oncology Group trials.
Critical Reviews in Oncology/Hematology 2008 65(2): 164-171
21.deJong, W. Phase III study of cyclophosphamide, doxorubicin, and etoposide compared
with carboplatin and paclitaxel in patients with extensive disease small-cell lung cancer.
European Journal of Cancer 2007 43(16): 2345-2350
22.Detterbeck, F. Neoadjuvant Chemotherapy with Gemcitabine-Containing Regimens in
Patients with Early-Stage Non-small Cell Lung Cancer. Journal of Thoracic Oncology.
3(1):37-45, January 2008.
23.Douillard, J. Comparison of Docetaxel- and Vinca Alkaloid-Based Chemotherapy in the
First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis of Seven
Randomized Clinical Trials. Journal of Thoracic Oncology. 2(10):939-946, October 2007.
24.Georgoulias, V. Docetaxel versus docetaxel plus gemcitabine as front-line treatment of
patients with advanced non-small cell lung cancer: A randomized, multicenter phase III trial.
Lung Cancer 2008 59(1): 57-63
25.Green, M. Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung
Cancer: Use Patterns among American Medical Oncologists 2000-2006. Journal of Thoracic
Oncology. 2(10):953-956, October 2007.
26.Gridelli C. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non
small-cell lung cancer: the MILES-2P studies. Journal of Clinical Oncology. 25(29):4663-9,
2007 Oct 10.
27.Heymach JV. Randomized, placebo-controlled phase II study of vandetanib plus
docetaxel in previously treated non small-cell lung cancer. Journal of Clinical Oncology.
25(27):4270-7, 2007 Sep 20.
28.Karrison TG. Design of phase II cancer trials using a continuous endpoint of change in
tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Journal of the National Cancer Institute. 99(19):1455-61, 2007 Oct 3.
29.Lecaer, H. An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score
and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell
lung cancer (NSCLC): The GFPC 02-02a study. Critical Reviews in Oncology/Hematology
2007 64(1): 73-81
30.O'Brien M. Recent advances with topotecan in the treatment of lung cancer. Oncologist.
12(10):1194-204, 2007 Oct.
31.Park JO. Phase III trial of two versus four additional cycles in patients who are
nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung
cancer. Journal of Clinical Oncology. 25(33):5233-9, 2007 Nov 20.
32.Pujol JL. Phase III double-blind, placebo-controlled study of thalidomide in extensivedisease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC
cleo04 IFCT 00-01. Journal of Clinical Oncology. 25(25):3945-51, 2007 Sep 1.
33.Rajeswaran, A. Efficacy and side effects of cisplatin- and carboplatin-based doublet
chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens
as first line treatment of metastatic non-small cell lung carcinoma: A systematic review of
randomized controlled trials. Lung Cancer 2008 59(1): 1-11
34.Waxman, E. Advances in Chemotherapy for Non–Small Cell Lung Cancer. Seminars in
Oncology Nursing 2008 24(1): 49-56
35.Weiss, G. Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer
(NSCLC) Patients: A Multicenter, Phase II Clinical Trial. Journal of Thoracic Oncology.
2(10):933-938, October 2007.
Prognostic and Risk Factors
36.Asamura, H. A Japanese Lung Cancer Registry Study: Prognosis of 13,010 Resected
Lung Cancers. Journal of Thoracic Oncology. 3(1):46-52, January 2008.
37.Berghmans, T. Primary Tumor Standardized Uptake Value (SUVmax) Measured on
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) is of Prognostic Value for
Survival in Non-small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-Analysis
(MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging
Project. Journal of Thoracic Oncology. 3(1):6-12, January 2008.
38.Booton R. ERCC1 mRNA expression is not associated with response and survival after
platinum-based chemotherapy regimens in advanced non-small cell lung cancer. Journal of
Thoracic Oncology: 2(10):902-6, 2007 Oct.
39.Bottomley A. Symptoms and patient-reported well-being: do they predict survival in
malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983:
randomized phase III study of cisplatin with or without raltitrexed in patients with malignant
pleural mesothelioma. Journal of Clinical Oncology. 25(36):5770-6, 2007 Dec 20.
40.Flores, R. Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a
Large Tertiary Referral Center. Journal of Thoracic Oncology. 2(10):957-965, October 2007.
41.Lee, P. Metabolic Tumor Burden Predicts for Disease Progression and Death in Lung
Cancer. International Journal of Radiation Oncology*Biology*Physics 2007 69(2): 328-333
42.Ramirez de Molina, A. Expression of choline kinase alpha to predict outcome in patients
with early-stage non-small-cell lung cancer: a retrospective study. The Lancet Oncology 2007
8(10): 889-897
Radiotherapy/Radiography
43.Bral, S. A feasibility study of image-guided hypofractionated conformal arc therapy for
inoperable patients with localized non-small cell lung cancer. Radiotherapy and Oncology
2007 84(3): 252-256
44.Dooms, C. Positron emission tomography in nonsmall cell lung cancer. Current Opinion in
Internal Medicine. 6(5):521-525, October 2007.
45.Grills, I. Clinicopathologic Analysis of Microscopic Extension in Lung Adenocarcinoma:
Defining Clinical Target Volume for Radiotherapy. International Journal of Radiation
Oncology*Biology*Physics 2007 69(2): 334-341
46.Haas, M. Advances in Radiation Therapy for Lung Cancer. Seminars in Oncology Nursing
2008 24(1): 34-40
47.Hayman, J. Use of Palliative Radiotherapy Among Patients With Metastatic Non–SmallCell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2007
69(4):1001-1007
48.Kepka, L. Delineation variation of lymph node stations for treatment planning in lung
cancer radiotherapy. Radiotherapy and Oncology 2007 85(3): 450-455
49.Klopp, A. Intrathoracic Patterns of Failure for Non–Small-Cell Lung Cancer With PositronEmission Tomography/Computed Tomography–Defined Target Delineation. International
Journal of Radiation Oncology*Biology*Physics 2007 69(5): 1409-1416
50.Koto, M. A phase II study on stereotactic body radiotherapy for stage I non-small cell lung
cancer. Radiotherapy and Oncology 2007 85(3): 429-434
51.Maxim, P. Quantification of Motion of Different Thoracic Locations Using Four-Dimensional
Computed Tomography: Implications for Radiotherapy Planning. International Journal of
Radiation Oncology*Biology*Physics 2007 69(5): 1395-1401
52.Miyamoto, T. Carbon Ion Radiotherapy for Stage I Non-small Cell Lung Cancer Using a
Regimen of Four Fractions during 1 Week. Journal of Thoracic Oncology. 2(10):916-926,
October 2007.
53.Onimaru, R. Steep Dose–Response Relationship for Stage I Non–Small-Cell Lung Cancer
Using Hypofractionated High-Dose Irradiation by Real-Time Tumor-Tracking Radiotherapy.
International Journal of Radiation Oncology*Biology*Physics 2008 70(2): 374-381
54.Rice, D. Dose-Dependent Pulmonary Toxicity After Postoperative Intensity-Modulated
Radiotherapy for Malignant Pleural Mesothelioma. International Journal of Radiation
Oncology*Biology*Physics 2007 69(2): 350-357
55.Seki, S. Differences in the definition of internal target volumes using slow CT alone or in
combination with thin-slice CT under breath-holding conditions during the planning of
stereotactic radiotherapy for lung cancer. Radiotherapy and Oncology 2007 85(3): 443-449
56.Sher, D. Quantification of Mediastinal and Hilar Lymph Node Movement Using FourDimensional Computed Tomography Scan: Implications for Radiation Treatment Planning.
International Journal of Radiation Oncology*Biology*Physics 2007 69(5): 1402-1408
57.Spiro, S. Ensuring the right PET scan for the right patient. Lung Cancer 2008 59(1): 48-56
58.Werner-Wasik, M. Increasing Tumor Volume is Predictive of Poor Overall and
Progression-Free Survival: Secondary Analysis of the Radiation Therapy Oncology Group 9311 Phase I-II Radiation Dose-Escalation Study in Patients with Inoperable Non–Small-Cell
Lung Cancer. International Journal of Radiation Oncology*Biology*Physics 2008 70(2): 385390
Screening/Staging/Polymorphisms/Biomarkers/Pathology
59.Bruderek, G. Malignant and non-malignant lung tissue areas are differentially populated by
natural killer cells and regulatory T cells in non-small cell lung cancer. Lung Cancer 2008
59(1): 32-40
60.Inamura, K. EML4-ALK Fusion Is Linked to Histological Characteristics in a Subset of Lung
Cancers. Journal of Thoracic Oncology. 3(1):13-17, January 2008.
61.Kawai, H. VEGF121 promotes lymphangiogenesis in the sentinel lymph nodes of nonsmall cell lung carcinoma patients. Lung Cancer 2008 59(1): 41-47
62.Miller, V. EGFR Mutations and EGFR Tyrosine Kinase Inhibition in Non–Small Cell Lung
Cancer. Seminars in Oncology Nursing 2008 24(1): 27-33
63.Smith, J. Lung Cancer Screening: Promise and Pitfalls. Seminars in Oncology Nursing
2008 24(1): 9-15
64.Suzuki, H. Decreased expression of the SIN3A gene, a candidate tumor suppressor
located at the prevalent allelic loss region 15q23 in non-small cell lung cancer. Lung Cancer
2008 59(1): 24-31
65.Tzannou, I. The Use of Radiolabeled Somatostatin Analog Scintigraphy in the Staging of
Small Cell Lung Cancer Patients. American Journal of Clinical Oncology. 30(5):503-506,
October 2007.
66.Von Haussen, J. The host defence peptide LL-37/hCAP-18 is a growth factor for lung
cancer cells. Lung Cancer 2008 59(1): 12-23
67.Weir, B.Characterizing the cancer
450(7171):893-898, December 6, 2007.
genome
in
lung
adenocarcinoma.
Nature.
Supportive Care
68.Chen L. Psychometric validation of the Patient Symptom Assessment in Lung Cancer
instrument for small cell lung cancer. Current Medical Research & Opinion. 23(11):2741-52,
2007 Nov.
69.Cooley, M. Smoking Cessation and Lung Cancer: Oncology Nurses Can Make a
Difference. Seminars in Oncology Nursing 2008 24(1):16-26
70.de Marinis, F. Lung Cancer Symptom Scale Outcomes in Relation to Standard Efficacy
Measures: An Analysis of the Phase III Study of Pemetrexed Versus Docetaxel in Advanced
Non-small Cell Lung Cancer. Journal of Thoracic Oncology. 3(1):30-36, January 2008.
71.Henoch, I. The Impact of Symptoms, Coping Capacity, and Social Support on Quality of
Life Experience Over Time in Patients with Lung Cancer. Journal of Pain and Symptom
Management 2007 34(4): 370-379
72.Joyce, M. Supportive Care in Lung Cancer. Seminars in Oncology Nursing 2008 24(1): 5767
73.Murray, S. Patterns of Social, Psychological, and Spiritual Decline Toward the End of Life
in Lung Cancer and Heart Failure. Journal of Pain and Symptom Management 2007 34(4):
393-402
Surgery
74.Ikeda, N. Surgical strategy for non-small cell lung cancer in octogenarians. Respirology.
12(5):712-718, September 2007.
75.Wagner, K. Surgical Management of Non–Small Cell Lung Cancer. Seminars in Oncology
Nursing 2008 24(1): 41-48
Related documents